Laboratory Corp of America Holdings Stock News

Laboratory Corporation of America Holdings (LH) Q4 2023 Earnings Conference Call Transcript

Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street

Labcorp (LH) came out with quarterly earnings of $3.30 per share, beating the Zacks Consensus Estimate of $3.29 per share. This compares to earnings of $4.14 per share a year ago.

Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LabCorp (LH) test System, which is available through clinicians, is the first FDA-cleared biomarker test to aid in the risk assessment of progression to severe preeclampsia.

Stocks such as EXAS, DGX and LH are likely to potentially continue the momentum in the oncology field.

LabCorp (LH) and Hawthorne Effect hope to enhance decentralized clinical trials by merging existing services and developing fresh, unique service offers.

Investors are increasingly optimistic about Labcorp (LH) due to development in targeted high-growth areas.

Labcorp (LH) finalizes the comprehensive laboratory relationship with Legacy Health.

Labcorp (LH) delivers a strong performance in the third quarter of 2023 across the Diagnostics Laboratories and Biopharma Laboratory Services businesses.

Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Stree

Labcorp (LH) came out with quarterly earnings of $3.38 per share, beating the Zacks Consensus Estimate of $3.37 per share. This compares to earnings of $4.68 per share a year ago.

Laboratory Corporation of America topped Wall Street expectations for quarterly adjusted profit on Thursday, as strength in its routine diagnostics business more than offset weak COVID test sales.

Labcorp's (LH) new test, ATN Profile, is likely to accelerate the path to the diagnosis of Alzheimer's disease.

Labcorp on Wednesday began marketing to U.S. physicians the first test for a trio of blood biomarkers it says can detect the hallmarks of Alzheimer's, accelerating diagnosis of the brain-wasting disea